Skip to content

A Clinical Study on "Triple Acupuncture Method" of the Combination of Traditional Chinese Medicine and Western Medicine in the Treatment of Neurosurgery Related Optic Pathway Injury

A Clinical Study on "Triple Acupuncture Method" of the Combination of Traditional Chinese Medicine and Western Medicine in the Treatment of Neurosurgery Related Optic Pathway Injury

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300079101
Enrollment
Unknown
Registered
2023-12-26
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurosurgery Related Optic Pathway Injury

Interventions

Triple Acupuncture Method Group:NA

Sponsors

General Hospital of Northern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged = 18; 2. Imaging diagnosis of compression or/and invasion of the optic pathway requiring neurosurgical treatment; 3. The best corrected visual acuity (BCVA) after surgery is = 0.1, and further "triple needle" rehabilitation treatment is required; 4. The condition is stable, the course of the disease is = 1 year, and the expected survival time is = 3 months; 5. The patients or their families agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Best corrected visual acuity (BCVA) after surgery<0.1 2. Merge other visual function diseases, retinal diseases, and optic nerve diseases that affect the accuracy of relevant examinations 3. Individuals who are unable to cooperate with ophthalmic examinations (cognitive impairment, hemiplegia, muscle tension, etc.) 4. Patients with coagulation disorders; 5. Pregnant/lactating women; 6. Mental illness where informed consent cannot be obtained; 7. Accompanied by other serious diseases that can shorten survival time; 8. Any unstable situation that may influence safety and compliance; 9. Have participated in other clinical trials within 30 days prior to the screening visit in this study; 10. The researchers believe that the subject is unlikely to complete this study.

Design outcomes

Primary

MeasureTime frame
Vision and field of vision;Efficacy evaluation;

Secondary

MeasureTime frame
Retinal nerve fiber layer (RNFL) thickness;

Countries

China

Contacts

Public ContactLiang Guobiao

General Hospital of Northern Theater Command

guobiaoliang@163.com+86 138 9886 6708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026